Non-anaphylactic combination of partially deleted fragments of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy.
Allergen-specific immunotherapy, in which repeated injections of allergens over prolonged periods are used to induce tolerance, has proven an effective treatment of allergy. A major side effect of allergen-specific immunotherapy is anaphylactic reaction. House dust mite allergens are major causative factors associated with various allergic diseases. Der f 2 is the major house dust mite allergen composed of 129 amino acid residues. Analysis using deletion mutants of Der f 2 suggested that T-cell epitopes of Der f 2 were multiple in mite-allergic patients. We found that some IgE epitopes were renatured by dialysis of a mixture of two denatured C- and N-terminal deletion mutants, 1-112 and 85-129 in 13 patients out of 14. On the other hand, IgE binding activity was negative in the separately dialyzed fragments and their mixture in each patient tested. Furthermore, we demonstrated that neither of the two separately prepared polypeptides induced in vivo skin prick test reactivity. These findings are important for improvement of T-cell targeting allergen-specific immunotherapy and development of monovalent IgE haptens. The use of combinations of overlapping non-anaphylactic fragments of allergen covering all of the T-cell epitopes achieves the removal of IgE reactivity, the cause of harmful anaphylactic reactions, without affecting the T-cell reactivity essential for immunotherapy, offering potentially safer and more effective treatment for allergic disease.
Takai
T
T
Bioscience Research and Development Laboratory, Asahi Breweries Ltd., Ibaraki, Japan. toshiro.takai@asahibeer.co.jp
Mori
A
A
Yuuki
T
T
Okudaira
H
H
Okumura
Y
Y
D000485:Allergens / Q000008:administration & dosage / Q000235:genetics* / Q000276:immunology*; D000707:Anaphylaxis / Q000517:prevention & control; D000818:Animals; D039741:Antigens, Dermatophagoides; D003888:Desensitization, Immunologic / Q000379:methods*; D004391:Dust; D000939:Epitopes / Q000737:chemistry / Q000235:genetics; D006023:Glycoproteins / Q000008:administration & dosage / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000276:immunology / Q000628:therapy; D007073:Immunoglobulin E / Q000097:blood; D008213:Lymphocyte Activation; D008925:Mites / Q000235:genetics / Q000276:immunology*; D010446:Peptide Fragments / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D015202:Protein Engineering; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D017384:Sequence Deletion; D012882:Skin Tests; D013601:T-Lymphocytes / Q000276:immunology
D000485:Allergens; D039741:Antigens, Dermatophagoides; D004391:Dust; D000939:Epitopes; D006023:Glycoproteins; D010446:Peptide Fragments; D011993:Recombinant Fusion Proteins; D007073:Immunoglobulin E